However, the application of TfR as a target for CAR T cell therapy in T-cell malignancies still faces the difficult problem met by many targetable antigens which are shared between normal and malignant T cells, resulting in the mutual killing of CAR T cells to greatly reduce their therapeutic efficacy (38). This evidence concerns the gene TFRC and cancer.